ENDONOVO THERAPEUTICS, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that ENDONOVO THERAPEUTICS, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2012 | Dec 31, 2012 | $30.6K | May 3, 2013 |
| FY2012 | Dec 31, 2011 | $0 | May 3, 2013 |
| FY2011 | Dec 31, 2010 | $51.2K | Apr 13, 2012 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $135.4K | Apr 17, 2023 |
| FY2022 | Dec 31, 2021 | $73.1K | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $165.8K | Apr 14, 2022 |
| FY2020 | Dec 31, 2019 | $310.2K | Apr 13, 2021 |
| FY2019 | Dec 31, 2018 | $83.3K | May 4, 2020 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2015 | $4.3K | Apr 17, 2017 |
| FY2015 | Dec 31, 2014 | $24.2K | May 17, 2016 |
| FY2014 | Dec 31, 2013 | $22.9K | Jun 15, 2015 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $125.4K | Apr 17, 2023 |
| FY2022 | Dec 31, 2021 | $58.1K | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $100.4K | Apr 14, 2022 |
| FY2020 | Dec 31, 2019 | $216.8K | Apr 13, 2021 |
| FY2019 | Dec 31, 2018 | $70.3K | May 4, 2020 |
| FY2016 | Dec 31, 2015 | $2.1K | Apr 17, 2017 |
| FY2015 | Dec 31, 2014 | $8.7K | May 17, 2016 |
| FY2014 | Dec 31, 2013 | $8.9K | Jun 15, 2015 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | ($18.47M) | Apr 17, 2023 |
| FY2022 | Dec 31, 2021 | ($3.10M) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($395.6K) | Apr 14, 2022 |
| FY2020 | Dec 31, 2019 | ($17.31M) | Apr 13, 2021 |
| FY2019 | Dec 31, 2018 | ($6.44M) | May 4, 2020 |
| FY2018 | Dec 31, 2017 | ($10.81M) | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | ($5.32M) | Apr 6, 2018 |
| FY2016 | Dec 31, 2015 | ($6.77M) | Apr 17, 2017 |
| FY2015 | Dec 31, 2014 | ($959.5K) | May 17, 2016 |
| FY2014 | Dec 31, 2013 | ($2.89M) | Jun 15, 2015 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | ($3.26M) | Apr 17, 2023 |
| FY2022 | Dec 31, 2021 | ($2.23M) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($2.91M) | Apr 14, 2022 |
| FY2020 | Dec 31, 2019 | ($3.81M) | Apr 13, 2021 |
| FY2019 | Dec 31, 2018 | ($4.16M) | May 4, 2020 |
| FY2018 | Dec 31, 2017 | ($4.60M) | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | ($5.41M) | Apr 6, 2018 |
| FY2016 | Dec 31, 2015 | ($2.56M) | Apr 17, 2017 |
| FY2015 | Dec 31, 2014 | ($2.19M) | May 17, 2016 |
| FY2014 | Dec 31, 2013 | ($2.43M) | Jun 15, 2015 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $0 | Apr 14, 2022 |
| FY2021 | Dec 31, 2020 | $3.3K | Apr 14, 2022 |
| FY2020 | Dec 31, 2019 | $153.1K | Apr 13, 2021 |
| FY2019 | Dec 31, 2018 | $274.3K | May 4, 2020 |
| FY2018 | Dec 31, 2017 | $115.2K | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | $0 | Apr 6, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | ($678.8K) | Apr 17, 2023 |
| FY2022 | Dec 31, 2021 | ($986.6K) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($741.6K) | Apr 14, 2022 |
| FY2020 | Dec 31, 2019 | ($2.54M) | Apr 13, 2021 |
| FY2019 | Dec 31, 2018 | ($2.88M) | May 4, 2020 |
| FY2018 | Dec 31, 2017 | ($2.99M) | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | ($2.46M) | Apr 6, 2018 |
| FY2016 | Dec 31, 2015 | ($1.02M) | Apr 17, 2017 |
| FY2015 | Dec 31, 2014 | ($909.3K) | May 17, 2016 |
| FY2014 | Dec 31, 2013 | ($257.4K) | Jun 15, 2015 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2019 | $2.6K | Apr 13, 2021 |
| FY2019 | Dec 31, 2018 | $9.0K | May 4, 2020 |
| FY2016 | Dec 31, 2015 | $3.8K | Apr 17, 2017 |
| FY2015 | Dec 31, 2014 | $0 | May 17, 2016 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $1.28M | Apr 17, 2023 |
| FY2022 | Dec 31, 2021 | $2.01M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $2.61M | Apr 14, 2022 |
| FY2020 | Dec 31, 2019 | $3.27M | Apr 13, 2021 |
| FY2019 | Dec 31, 2018 | $4.24M | May 4, 2020 |
| FY2018 | Dec 31, 2017 | $4.61M | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | $318.7K | Apr 6, 2018 |
| FY2016 | Dec 31, 2015 | $409.4K | Apr 17, 2017 |
| FY2015 | Dec 31, 2014 | $45.6K | May 17, 2016 |
| FY2014 | Dec 31, 2013 | $73.6K | Jun 15, 2015 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $33.46M | Apr 17, 2023 |
| FY2022 | Dec 31, 2021 | $17.78M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $16.98M | Apr 14, 2022 |
| FY2020 | Dec 31, 2019 | $23.78M | Apr 13, 2021 |
| FY2019 | Dec 31, 2018 | $15.63M | May 4, 2020 |
| FY2018 | Dec 31, 2017 | $14.16M | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | $8.88M | Apr 6, 2018 |
| FY2016 | Dec 31, 2015 | $9.69M | Apr 17, 2017 |
| FY2015 | Dec 31, 2014 | $4.74M | May 17, 2016 |
| FY2014 | Dec 31, 2013 | $4.21M | Jun 15, 2015 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | ($32.18M) | Apr 17, 2023 |
| FY2022 | Dec 31, 2021 | ($15.77M) | Apr 17, 2023 |
| FY2022 | Dec 31, 2020 | ($14.37M) | Apr 17, 2023 |
| FY2021 | Dec 31, 2019 | ($20.50M) | Apr 14, 2022 |
| FY2020 | Dec 31, 2018 | ($11.39M) | Apr 13, 2021 |
| FY2019 | Dec 31, 2017 | ($9.55M) | May 4, 2020 |
| FY2018 | Dec 31, 2016 | ($8.56M) | Apr 15, 2019 |
| FY2017 | Dec 31, 2015 | ($9.28M) | Apr 6, 2018 |
| FY2016 | Dec 31, 2014 | ($4.69M) | Apr 17, 2017 |
| FY2015 | Dec 31, 2013 | ($4.13M) | May 17, 2016 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2014 | Dec 31, 2013 | $197.8K | Jun 15, 2015 |
| FY2014 | Nov 16, 2013 | $96.3K | Jun 15, 2015 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | ($75.12M) | Apr 17, 2023 |
| FY2022 | Dec 31, 2021 | ($56.44M) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($53.34M) | Apr 14, 2022 |
| FY2020 | Dec 31, 2019 | ($52.93M) | Apr 13, 2021 |
| FY2019 | Dec 31, 2018 | ($35.62M) | May 4, 2020 |
| FY2018 | Dec 31, 2017 | ($29.18M) | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | ($18.37M) | Apr 6, 2018 |
| FY2016 | Dec 31, 2015 | ($13.06M) | Apr 17, 2017 |
| FY2015 | Dec 31, 2014 | ($6.29M) | May 17, 2016 |
| FY2014 | Dec 31, 2013 | ($5.33M) | Jun 15, 2015 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $85.9K | Apr 14, 2022 |
| FY2021 | Dec 31, 2020 | $13.4K | Apr 14, 2022 |
| FY2020 | Dec 31, 2019 | $18.9K | Apr 13, 2021 |
| FY2019 | Dec 31, 2018 | $379.2K | May 4, 2020 |
| FY2018 | Dec 31, 2017 | $90.2K | Apr 15, 2019 |
| FY2018 | Dec 31, 2016 | $55.5K | Apr 15, 2019 |
| FY2017 | Dec 31, 2015 | $41.5K | Apr 6, 2018 |
| FY2016 | Dec 31, 2014 | $988 | Apr 17, 2017 |
| FY2015 | Dec 31, 2013 | $3.3K | May 17, 2016 |
| FY2014 | Dec 31, 2012 | $800 | Jun 15, 2015 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $7.15M | Apr 17, 2023 |
| FY2021 | Dec 31, 2021 | $7.26M | Apr 14, 2022 |
| FY2020 | Dec 31, 2020 | $6.84M | Apr 13, 2021 |
| FY2019 | Dec 31, 2019 | $6.87M | May 4, 2020 |
| FY2018 | Dec 31, 2018 | $8.16M | Apr 15, 2019 |
| FY2017 | Dec 31, 2017 | $7.36M | Apr 6, 2018 |
| FY2016 | Dec 31, 2016 | $3.19M | Apr 17, 2017 |
| FY2015 | Dec 31, 2015 | $28.6K | May 17, 2016 |
| FY2014 | Dec 31, 2014 | $1.57M | Jun 15, 2015 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | 0 | Apr 17, 2023 |
| FY2022 | Dec 31, 2021 | 0 | Apr 17, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | 213.23M | Apr 17, 2023 |
| FY2022 | Dec 31, 2021 | 74.50M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | 24.54M | Apr 14, 2022 |
| FY2020 | Dec 31, 2019 | 1.19M | Apr 13, 2021 |
| FY2019 | Dec 31, 2018 | 431,063 | May 4, 2020 |
| FY2018 | Dec 31, 2017 | 316.95M | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | 134.34M | Apr 6, 2018 |
| FY2015 | Mar 24, 2016 | 108.03M | May 17, 2016 |
| FY2016 | Dec 31, 2015 | 104.80M | Apr 17, 2017 |
| FY2015 | Nov 16, 2015 | 103.29M | May 17, 2016 |